Metrics of progression and prognosis in untreated adults with thymidine kinase 2 deficiency: An observational study.

Clinical trials (observational study) Creatinine Mitochondrial disease Thymidine kinase 2 deficiency

Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
09 2022
Historique:
received: 20 01 2022
revised: 23 06 2022
accepted: 13 07 2022
pubmed: 31 7 2022
medline: 21 9 2022
entrez: 30 7 2022
Statut: ppublish

Résumé

This historical cohort study evaluated clinical characteristics of progression and prognosis in adults with thymidine kinase 2 deficiency (TK2d). Records were available for 17 untreated adults with TK2d (mean age of onset, 32 years), including longitudinal data from 6 patients (mean follow-up duration, 26.5 months). Pearson's correlation assessed associations between standard motor and respiratory assessments, clinical characteristics, and laboratory values. Longitudinal data were assessed by linear regression mixed models. Respiratory involvement progressed at an annual rate of 8.16% decrement in forced vital capacity (FVC). Most patients under noninvasive ventilation (NIV) remained ambulant (12/14, 86%), reduced FVC was not associated with concomitant decline in 6-minute walk test (6MWT), and 6MWT results were not correlated with FVC. Disease severity, assessed by age at NIV onset, correlated most strongly at diagnosis with: creatinine levels (r = 0.8036; P = 0.0009), followed by FVC (r = 0.7265; P = 0.0033), mtDNA levels in muscle (r = 0.7933; P = 0.0188), and age at disease onset (r = 0.7128; P = 0.0042). This population of adults with TK2d demonstrates rapid deterioration of respiratory muscles, which progresses independently of motor impairment. The results support FVC at diagnosis, mtDNA levels in muscle, and age at disease onset as prognostic indicators. Creatinine levels may also be potentially prognostic, as previously reported in other neuromuscular disorders.

Identifiants

pubmed: 35907766
pii: S0960-8966(22)00601-0
doi: 10.1016/j.nmd.2022.07.399
pii:
doi:

Substances chimiques

DNA, Mitochondrial 0
Creatinine AYI8EX34EU
thymidine kinase 2 EC 2.7.1.-
Thymidine Kinase EC 2.7.1.21

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

728-735

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Auteurs

Cristina Domínguez-González (C)

Neuromuscular Disorders Unit, Neurology Department, Hospital 12 de Octubre, Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigación imas12, Hospital 12 de Octubre, Madrid, Spain. Electronic address: cdgonzalez@salud.madrid.org.

Ana Hernández-Voth (A)

Pneumology Department, Mechanical Ventilation Unit, Hospital 12 de Octubre, Madrid, Spain.

Carlos Pablo de Fuenmayor-Fernández de la Hoz (CP)

Neuromuscular Disorders Unit, Neurology Department, Hospital 12 de Octubre, Madrid, Spain.

Laura Bermejo Guerrero (LB)

Neuromuscular Disorders Unit, Neurology Department, Hospital 12 de Octubre, Madrid, Spain.

Germán Morís (G)

Neuromuscular Disorders Unit, Neurology Department, Hospital Universitario Central de Asturias, Asturias, Spain.

Jorge García-García (J)

Department of Neurology, Hospital Universitario de Albacete, Albacete, Spain.

Nuria Muelas (N)

Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain; Neurology Department, Neuromuscular Diseases Unit. Hospital Universitari i Politecnic La Fe, Neuromuscular and Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

Juan Carlos León Hernández (JC)

Neurology Department, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain.

Maria Rabasa (M)

Neurology Department, Hospital de Fuenlabrada, Madrid, Spain.

David Lora (D)

Clinical Research Unit, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Departamento de Estadística y Ciencia de los Datos, Facultad de Estudios Estadísticos, Universidad Complutense de Madrid, 28040 Madrid, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Alberto Blázquez (A)

Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain; Research Institute imas12, Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Joaquín Arenas (J)

Research Institute imas12, Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Miguel Ángel Martin (MÁ)

Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain; Research Institute imas12, Mitochondrial Disorders Laboratory, Clinical Biochemistry Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH